THERAPY DOSSIER · th-179b53887b46

1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol (PLAG)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 8

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT06487000 ↗PHASE2not yet recruiting

Phase 2 Trial of EC-18 in Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

Enrolment: 150 · Results not recorded

NCT04500132 ↗PHASE2completed

Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia

COVID-19

Enrolment: 63 · Results not recorded

NCT03200340 ↗PHASE2completed

EC-18 for Oral Mucositis in Patients With Concomitant Chemoirradiation for Head and Neck Cancers

Stomatitis

Enrolment: 105 · Results not recorded

NCT04569227 ↗PHASE2unknown

EC-18 in Preventing Progression of COVID-19 Infection to Severe Pneumonia or ARDS

Covid19 Pneumonia

Enrolment: 60 · Results not recorded

NCT03104595 ↗PHASE1/PHASE2completed

EC-18 for Management of Chemotherapy-Induced Neutropenia in Advanced Breast Cancer

Febrile Neutropenia

Enrolment: 28 · Results not recorded

NCT02700360 ↗PHASE1completed

Effect of Food on Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Volunteers

Chemotherapy-Induced Neutropenia

Enrolment: 36 · Results not recorded

NCT02532712 ↗PHASE1completed

Single and Multiple Ascending Dose Escalation Phase I Trial of EC-18 in Healthy Male Volunteers

Chemotherapy-Induced Neutropenia

Enrolment: 64 · Results not recorded

NCT02496143 ↗PHASE1completed

Single-Ascending-Dose Study of Safety, Tolerability, PK and PD of Oral EC-18 in Healthy Subjects

Chemotherapy-induced Neutropenia

Enrolment: 33 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31556847 ↗2019Reported benefit

Mitigating Effects of 1-Palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol (PLAG) on Hematopoietic Acute Radiation Syndrome after Total-Body Ionizing Irradiation in Mice.

MouseRadiationBALB/cmale and female50 mg/kg and 250 mg/kgPost-irradiation, including delayed administration at 48 h and 72 h after gamma…

Model: Single-fraction gamma-ray total-body irradiation causing haematopoietic acute radiation syndrome

PLAG dose-dependently attenuated radiation-induced mortality and body weight loss, delayed onset and shortened duration of severe neutropenia, and mitigated thrombocytopenia and anaemia; delayed dosing at 48 h and 72 h still improved survival.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…